Eupraxia Reports Durable EoE Symptom Improvements With EP-104GI
VANCOUVER, British Columbia, August 13, 202 Eupraxia Pharmaceuticals Inc. reported new symptom-response data from the ongoing Phase 1b/2a portion...
Phase 2a
Advertisement
BioInvent Receives FDA Fast Track Designation for BI-1808
LUND, Sweden, August 7, 2026 BioInvent International AB announced that the U.S. Food and Drug Administration (FDA) has granted...
Theriva Biologics Advances VCN-01 in Pancreatic Cancer
ROCKVILLE, Md., August 6, 2026 Theriva Biologics announced that the first patient has been dosed in the VIRAGE2 Phase...
4Moving Biotech Targets Synovitis with Intra-Articular GLP-1 Therapy
LILLE & PARIS, France, Aug. 4, 2026 4Moving Biotech (4MB) announced the completion of patient enrollment in the Phase...
Medicus Pharma Receives UAE IND Authorization for PRECISION-E2 Study
PHILADELPHIA, July 31, 2026 Medicus Pharma Ltd. announced that the United Arab Emirates (UAE) Department of Health – Abu...
Advertisements
Humacyte FDA Accepts IND for First-in-Human CTEV CABG Study
DURHAM, N.C., July 27, 2026 Humacyte, Inc. announced that the U.S. Food and Drug Administration (FDA) has accepted its...
Can-Fite Phase 2a Namodenoson Pancreatic Cancer Data Accepted at ESMO 2026
RAMAT GAN, Israel, July 20, 2026 Can-Fite BioPharma Ltd. (NYSE American: CANF) announced that positive Phase 2a clinical trial...
Kenai Therapeutics Completes Phase 1b/2a REPLACE Trial Enrollment
SAN DIEGO, July 7, 2026 Kenai Therapeutics has announced the successful completion of patient enrollment in the Phase 1b/2a...
Can-Fite Reports Positive Phase 2a Namodenoson Safety Datar
Ramat Gan, Israel, July 1, 2026 Can-Fite BioPharma Ltd. announced that its Phase 2a clinical study evaluating Namodenoson in...
Wave Life Sciences Initiates Phase 2a INLIGHT™ Trial of WVE-007 for Obesity and Cardiometabolic Diseases
CAMBRIDGE, Mass., June 24, 2026 Wave Life Sciences announced the initiation of the Phase 2a multidose portion of the...
Advertisement
